Variations in Gene Expression and Response to Neoadjuvant Chemotherapy in Breast Carcinoma

REFERENCES

• van der Hage J. A., van de Velde C. J., Julien J. P., Tubiana-Hulin M., Vandervelden C., Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19(22)4224–4237
   PubMed Web of Science ®Google Scholar
• Launchbury A. P., Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity, and toxicity. Cancer Treat Rev 1993; 19(3)197–228
   PubMed Web of Science ®Google Scholar
• Amat S., Bougnoux P., Penault-Llorca F., Fétissof F., Curé H., Kwiatkowski F., Achard J. L., Body G., Dauplat J., Chollet P. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003; 88(9)1339–1345
   PubMed Web of Science ®Google Scholar
• Airoldi M., Cattel L., Pedani F., Marchionatti S., Tagini V., Bumma C., Recalenda V. Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Breast Cancer Res Treat 2001; 70(3)185–195
   PubMed Web of Science ®Google Scholar
• Sotiriou C., Powles T. J., Dowsett M., Jazaeri A. A., Feldman A. L., Assersohn L., Gadisetti C., Libutti S. K., Liu E. T. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002; 4(3)R3
   PubMed Web of Science ®Google Scholar
• Chang J. C., Wooten E. C., Tsimelzon A., Hilsenbeck S. G., Gutierrez M. C., Elledge R., Mohsin S., Osborne C. K., Chamness G. C., Allred D. C., O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362(9381)362–369
   PubMed Web of Science ®Google Scholar
• Ayers M., Symmans W. F., Stec J., Damokosh A. I., Clark E., Hess K., Lecocke M., Metivier J., Booser D., Ibrahim N., Valero V., Royce M., Arun B., Whitman G., Ross J., Sneige N., Hortobagyi G. N., Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22(12)2284–2293
   PubMed Web of Science ®Google Scholar
• Folgueira M. A., Carraro D. M., Brentani H., Patrão D. F., Barbosa E. M., Netto M. M., Caldeira J. R., Katayama M. L., Soares F. A., Oliveira C. T., Reis L. F., Kaiano J. H., Camargo L. P., Vêncio R. Z., Snitcovsky I. M., Makdissi F. B., e Silva P. J., Góes J. C., Brentani M. M. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005; 11(20)7434–7443
   PubMed Web of Science ®Google Scholar
• Hannemann J., Oosterkamp H. M., Bosch C. A.J., Velds A., Wessels L. F., Loo C., Rutgers E. J., Rodenhuis S., van de Vijver M. J. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23(15)3331–3342
   PubMed Web of Science ®Google Scholar
• Dressman H. K., Hans C., Bild A., Olson J. A., Rosen E., Marcom P. K., Liotcheva V. B., Jones E. L., Vujaskovic Z., Marks J., Dewhirst M. W., West M., Nevins J. R., Blackwell K. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006; 12(3 Pt 1)819–826
   PubMed Web of Science ®Google Scholar
• Thuerigen O., Schneeweiss A., Toedt G., Warnat P., Hahn M., Kramer H., Brors B., Rudlowski C., Benner A., Schuetz F., Tews B., Eils R., Sinn H. P., Sohn C., Lichter P. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24(12)1839–1845
   PubMed Web of Science ®Google Scholar
• Modlich O., Prisack H. B., Munnes M., Audretsch W., Bojar H. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004; 10(19)6418–6431
   PubMed Web of Science ®Google Scholar
• Sotiriou C., Desmedt C. Gene expression profiling in breast cancer. Ann Oncol 2006; 17(Suppl 10)x259–262
   Google Scholar
• Luporsi E., Vanlemmens L., Coudert B. Six cycles of FEC 100 vs six cycles of epirubicin/docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: results of a randomized phase II trial of GIREC S01. Presented at the 36th Annual ASCO Meeting. Cancer Conf Highlights 2000; 4: 2–4
   Google Scholar
• Chollet P., Amat S., Cure H., de Latour M., Le Bouedec G., Mouret-Reynier M. A., Ferriere J. P., Achard J. L., Dauplat J., Penault-Llorca F. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86(7)1041–1046
   PubMed Web of Science ®Google Scholar
• Arnal M., Franco N., Fargeot P., Riedinger J. M., Brunet-Lecomte P., Lizard-Nacol S. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 2000; 61(1)13–20
   PubMed Web of Science ®Google Scholar
• Livak K. J., Schmittgen T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001; 25(4)402–408
   PubMed Web of Science ®Google Scholar
• Perou C. M., Sørlie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Rees C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge O., Pergamenschikov A., Williams C., Zhu S. X., Lønning P. E., Børresen-Dale A. L., Brown P. O., Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406(6797)747–752
   PubMed Web of Science ®Google Scholar
• Troester M. A., Hoadley K. A., Sørlie T., Herbert B. S., Børresen-Dale A. L., Lønning P. E., Shay J. W., Kaufmann W. K., Perou C. M. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004; 64(12)4218–4226
   PubMed Web of Science ®Google Scholar
• Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., Mariani G., Rodriguez J., Carcangiu M., Watson D., Valagussa P., Rouzier R., Symmans W. F., Ross J. S., Hortobagyi G. N., Pusztai L., Shak S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23(29)7265–7277
   PubMed Web of Science ®Google Scholar
• Minna J. D., Girard L., Xie Y. Tumor mRNA expression profiles predicts responses to chemotherapy. J Clin Oncol 2007; 25(28)4329–4336
   PubMed Web of Science ®Google Scholar
• Sotiriou C., Piccart M. J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007; 7(7)545–553
   PubMed Web of Science ®Google Scholar
• Korn E. L., McShane L. M., Troendle J. F., Rosenwald A., Simon R. Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002; 86(7)1093–1096
   PubMed Web of Science ®Google Scholar
• Dupuy A., Simon R. M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007; 99(2)147–157
   PubMed Web of Science ®Google Scholar
• Espinosa E., Fresno-Vara J. A., Redondo A., Sánchez J. J., Hardisson D., Zamora P., Pastrana F. G., Cejas P., Martínez B., Suárez A., Calero F., Barón M. G. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 2005; 23(29)7278–7285
   PubMed Web of Science ®Google Scholar
• Ioannidis J. P.A. Microarrays and molecular research: noise discovery?. Lancet 2005; 365(9458)454–455
   PubMed Web of Science ®Google Scholar
• Michiels S., Koscielny S., Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365(9458)488–492
   PubMed Web of Science ®Google Scholar
• Febbo P. G., Kantoff P. W. Noise and bias in microarray analysis of tumour specimens. J Clin Oncol 2006; 24(23)3719–3720
   PubMed Web of Science ®Google Scholar
• Bellamy C. O. p53 and apoptosis. Br Med Bull 1997; 53(3)522–538
   PubMed Web of Science ®Google Scholar
• Morse D. L., Gray H., Payne C. M., Gillies R. J. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005; 4(10)1495–1504
   PubMed Web of Science ®Google Scholar
• Harris S. R., Schoeffner D. J., Yoshiji H., Thorgeirsson U. P. Tumor-growth-enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett 2002; 179(1)95–101
   PubMed Web of Science ®Google Scholar